Safety and efficacy of percutaneous balloon mitral valvotomy in severe mitral stenosis with moderate mitral regurgitation – A prospective study

Vinayakumar, Desabandhu; Peringadan, Nithin Gopalan; Krishnan, M.N.

doi:10.1016/j.ihj.2016.04.025

Cited by 9 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the co-existence of moderate MR is considered PMBV contraindication, mitral valve replacement surgery is the routine practice for these patients thus exposing them to the risks of surgical complications, infective endocarditis and anticoagulation [3] , [21] . For that reason, Desabandhu et al 2016 [1] hypothesized that preserving the native valve via PMBV could be a safe and effective alternative measure that provides sustained symptomatic relief. Therefore, they compared the safety and efficacy of PMBV in patients with severe MS and moderate MR (group I, n = 17) with those with less than moderate or no MR (group II, n = 208).…”

Section: Discussionmentioning

confidence: 99%

“…Mitral stenosis (MS) is a disabling disease that limits the normal physical abilities of patients and considered as a major reason for hospital admissions [1] . The leading cause of MS globally is rheumatic heart disease RHD which remains common in economically developing countries and continues to be a significant cause of morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of percutaneous mitral balloon valvotomy in patients with mitral stenosis: A systematic review and meta-analysis

Rmilah

Tahboub

Alkurashi

et al. 2021

IJC Heart & Vasculature

View full text Add to dashboard Cite

Aims Percutaneous mitral balloon valvotomy PMBV is an acceptable alternative to Mitral valve surgery for patients with mitral stenosis. The purpose of this study was to explore the immediate results of PMBV with respect to echocardiographic changes, outcomes, and complications, using a meta -analysis approach. Methods MEDLINE, and EMBASE databases were searched (01/2012 to 10/2018) for original research articles regarding the efficacy and safety of PMBV. Two reviewers independently screened references for inclusion and abstracted data including article details and echocardiographic parameters before and 24–72 h after PMBV, follow-up duration, and acute complications. Disagreements were resolved by third adjudicator. Quality of all included studies was evaluated using the Newcastle-Ottawa Scale NOS. Results 44/990 references met the inclusion criteria representing 6537 patients. Our findings suggest that PMBV leads to a significant increase in MVA (MD = 0.81 cm 2 ; 0.76–0.87, p < 0.00001), LVEDP (MD = 1.89 mmHg; 0.52–3.26, p = 0.007), LVEDV EDV (MD = 5.81 ml; 2.65–8.97, p = 0.0003) and decrease in MPG (MD = −7.96 mmHg; −8.73 to −7.20, p < 0.00001), LAP (MD = −10.09 mmHg; −11.06 to −9.12, p < 0.00001), and SPAP (MD = −15.55 mmHg; −17.92 to −13.18, p < 0.00001). On short term basis, the pooled overall incidence estimates of repeat PMBV, mitral valve surgery, post-PMBV severe MR, and post-PMBV stroke, and systemic thromboembolism were 0.5%, 2%, 1.4%, 0.4%, and 0.7%% respectively. On long term basis, the pooled overall incidence estimates of repeat PMBV, mitral valve surgery, post-PMBV severe MR, and post-PMBV stroke, systemic thromboembolism were 5%, 11.5%, 5.5%, 2.7%, and 1.7% respectively Conclusion PMBV represents a successful approach for patients with mitral stenosis as evidenced by improvement in echocardiographic parameters and low rate of complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of percutaneous mitral balloon valvotomy in patients with mitral stenosis: A systematic review and meta-analysis

Rmilah

Tahboub

Alkurashi

et al. 2021

IJC Heart & Vasculature

View full text Add to dashboard Cite

show abstract

“…The first successful PBMV was made in 1984 by Inoue (4). The Inoue technique can be widely accepted and used more widely for PBMV (5). General complications of PBMV are acute mitral regurgitation (MR), thromboembolism, and cardiac perforation.…”

Section: Discussionmentioning

confidence: 99%

Is mitral balloon valvuloplasty really innocent?: A case report of right ventricular rupture

Sicim¹,

Demi̇rdaş²,

Kartal³

et al. 2020

GMJ

View full text Add to dashboard Cite

Percutaneous mitral balloon valvuloplasty (PMBV) is the primary treatment modality in patients with mitral stenosis without contraindications and with appropriate valve anatomy. In the literature, the mortality rate associated with PMBV was reported to be 1%. This process may cause rare and serious complications; such as pericardial effusion, acute mitral regurgitation, cardiac tamponade, and thrombus formation. In this case report, we present a 45-year-old female patient who underwent emergency surgery because of right ventricular rupture during PMBV.

show abstract

“…In our study, the success rate for procedures was 77.7% in group 1 and 60% in group 2; however, there was no significant difference between the groups. And improvement in MVA was accomplished in both groups.One of the high volume studies is the study of Desabandhu et al(16). They compared patients undergoing PMBV either with no or mild MR and moderate MR.…”

mentioning

confidence: 99%

Outcomes of Percutaneous Balloon Mitral Valvuloplasty in Significant Mitral Stenosis with Moderate Mitral Regurgitation - Single Center Study

Çelik¹,

Şahin²,

Karakayalı³

2021

BMB

View full text Add to dashboard Cite

Rheumatic heart disease is the deposition of immune complexes which cause malfunction of the heart valves. Percutaneous mitral balloon valvuloplasty (PMBV) is an established treatment option in patients with symptomatic moderate or severe rheumatic mitral valve disease, but PMBV is not a preferred option in mitral stenosis (MS) patients with moderate mitral regurgitation (MR) due to the risk of severe MR. The aim of this study was to evaluate the safety and feasibility of PMBV in symptomatic MS patients with moderate MR by comparing the post-procedural parameters with those of MS patients with mild or no MR.Method: Among 104 patients with symptomatic MS, 10 patients with moderate MR were classified as group 2 while 94 patients who had mild or none MR were classified as group 1 in the present work. All patients underwent PMBV and pre-and post-procedural mitral valve area, MRs were recorded and cardiovascular events and complications were assessed in 30 days. Results:The only difference in both groups before and after the procedure was the severity of the MR. Cardiovascular death was not observed for both groups in 30 days. In group 1, there were 3 patients and in group 2, there was 1 patient who developed severe MR after PMBV. All patients who had post-procedural severe MR required mitral valve replacement in 30 days due to severe MR in group 1. The composite complication rate was similar between the groups. Conclusion:PMBV might be an alternative treatment option for selected patients having significant MS with moderate MR.

show abstract

Safety and efficacy of percutaneous balloon mitral valvotomy in severe mitral stenosis with moderate mitral regurgitation – A prospective study

Abstract: In patients having severe MS associated with moderate MR, PBMV may be a safe option and provides sustained symptomatic benefit.

Cited by 9 publications

References 10 publications

Efficacy and safety of percutaneous mitral balloon valvotomy in patients with mitral stenosis: A systematic review and meta-analysis

Efficacy and safety of percutaneous mitral balloon valvotomy in patients with mitral stenosis: A systematic review and meta-analysis

Is mitral balloon valvuloplasty really innocent?: A case report of right ventricular rupture

Outcomes of Percutaneous Balloon Mitral Valvuloplasty in Significant Mitral Stenosis with Moderate Mitral Regurgitation - Single Center Study

Contact Info

Product

Resources

About